Skip to main content
Nkarta, Inc. logo

Nkarta, Inc. — Investor Relations & Filings

Ticker · NKTX ISIN · US65487U1088 US Manufacturing
Open in API
Filings indexed 411 across all filing types
Latest filing 2026-04-03 Capital/Financing Update
Country US United States of America
Listing US NKTX

About Nkarta, Inc.

https://www.nkartatx.com/

Nkarta, Inc. is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies. The company's proprietary technology is designed to engineer NK cells to target and eliminate dysfunctional or diseased cells. Nkarta's primary focus is on developing treatments for B cell-mediated autoimmune diseases, with clinical programs investigating therapies for conditions such as lupus nephritis. The company's platform also has applications in oncology. Nkarta aims to provide accessible cell therapies that can reset a disordered immune system and offer new therapeutic options for patients.

Recent filings

Filing Released Lang Actions
424B5 - Nkarta, Inc. (0001787400) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a prospectus filed pursuant to Rule 424(b)(5) under the Securities Act of 1933. It is a registration statement related to an "at-the-market offering" of common stock by Nkarta, Inc., with details about the sales agreement, risk factors, use of proceeds, and other offering-related information. The document is not a financial report, earnings release, management discussion, or any other type of corporate filing related to financial results or governance. It is a capital raising document describing the terms and conditions of a stock offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is a full prospectus, not a brief announcement or regulatory filing. Confidence is high due to clear identification of the document type and regulatory references.
2026-04-03 English
S-3 - Nkarta, Inc. (0001787400) (Filer)
Regulatory Filings
2026-03-25 English
8-K - Nkarta, Inc. (0001787400) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically states that the company issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2025, and that the press release is attached as an exhibit. The document itself does not contain the full financial results or detailed financial statements but rather announces the release of those results. The document length is 3751 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such a document that announces the release of a report or financial results but does not contain the full report itself should be classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not fit other specific categories like Earnings Release (ER) which requires key highlights, or Annual Report (10-K) which requires full financial performance. Therefore, the appropriate classification is Regulatory Filings (RNS).
2026-03-25 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-17 English
4
Director's Dealing
2026-01-20 English
4
Director's Dealing
2026-01-20 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.